Aimmune Therapeutics Inc (AIMT) Insider Sells $233,093.12 in Stock

Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Mary M. Rozenman sold 6,592 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $35.36, for a total value of $233,093.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of Aimmune Therapeutics Inc (NASDAQ AIMT) traded down $0.86 during trading hours on Monday, reaching $35.32. The company’s stock had a trading volume of 366,114 shares, compared to its average volume of 410,338. The stock has a market capitalization of $1,800.00 and a PE ratio of -15.09. Aimmune Therapeutics Inc has a fifty-two week low of $15.97 and a fifty-two week high of $40.65.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.09. equities analysts expect that Aimmune Therapeutics Inc will post -2.51 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Aimmune Therapeutics by 12.6% in the second quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock worth $50,923,000 after buying an additional 276,978 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Aimmune Therapeutics by 10.2% in the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after buying an additional 101,855 shares during the period. State Street Corp raised its stake in shares of Aimmune Therapeutics by 26.6% in the second quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock worth $22,351,000 after buying an additional 228,429 shares during the period. Citadel Advisors LLC raised its stake in shares of Aimmune Therapeutics by 3,092.5% in the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after buying an additional 542,111 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Aimmune Therapeutics by 24.7% in the second quarter. Northern Trust Corp now owns 391,990 shares of the biotechnology company’s stock worth $8,059,000 after buying an additional 77,744 shares during the period. 73.54% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have issued reports on AIMT shares. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Saturday, October 21st. Wedbush reissued an “outperform” rating and issued a $70.00 target price (up from $42.00) on shares of Aimmune Therapeutics in a research report on Monday, October 23rd. Credit Suisse Group raised their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Finally, Roth Capital started coverage on Aimmune Therapeutics in a research report on Monday, November 20th. They issued a “buy” rating and a $60.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. Aimmune Therapeutics currently has an average rating of “Hold” and an average price target of $57.57.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/05/aimmune-therapeutics-inc-aimt-insider-sells-233093-12-in-stock.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply